Trial Profile

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doravirine/islatravir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
Indications HIV-1 infections
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms DOR/ISL Blinded Label Switch; ILLUMINATE SWITCH B
Sponsors Merck Sharp & Dohme Corp.

30 Mar 2025 Status changed from suspended to completed.
26 Jun 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
28 Feb 2024 Planned End Date changed from 31 May 2024 to 25 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com